pharma · HIV Infections · Major Depressive Disorder · PRAX
Praxis Precision Medicines drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Praxis Precision Medicines drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
Development asset linked to Praxis Precision Medicines in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
Development asset linked to Praxis Precision Medicines in public FDA and regional records.
US regulatory status: approved.
US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 1.
Development asset linked to Praxis Precision Medicines in public FDA and regional records.